Prostate Cancer

Higher cardiorespiratory fitness linked to lower risk of death from colon, lung, prostate cancers

Approval limited to BRCA-positive subset

Systematic reviews suggests increased risks of cognitive adverse events, fatigue, falls

Should very low-risk and low-risk be combined into one?

Combo has potential to be new standard of care in patients with high-risk BCR, expert says

ODAC votes that olaparib-abiraterone combination should be restricted to BRCA-positive subset

Agency asking ODAC if olaparib-abiraterone should be reserved for BRCA-positive subset

All but one patient had a PSA decline after a fractionated dose of 225Ac-J591

PSA screening rates over 50% for men 70 and up, despite USPSTF recommendations against it

Consider "trade-offs" between harms and benefits of treatments, say researchers

Also in TTHealthWatch: low-risk prostate cancer in the U.S.

And rates still remain "suboptimal," argue researchers

Health news and commentary from around the Web gathered by MedPage Today staff

But add-on abiraterone and apalutamide may offer some benefits in those with higher PSA